Treatment for Mast Cell Tumors in Cats

Rassnick, K. M., L. E. Williams, et al. (2008). "Lomustine for treatment of mast cell tumors in cats: 38 cases (1999-2005)." J Am Vet Med Assoc 232(8): 1200-5.


Mast cell tumours (MCTs) are commonly diagnosed in cats, particularly in cutaneous locations. These tumours have a range of biological behavior from benign to malignant. Most cutaneous MCTs are readily treated with surgery or local radiation. Alternative treatments are needed for those cats where surgery or radiation is not an option, or where these modalities have failed to prevent recurrence. In this retrospective case series, the clinical efficacy and toxicity of lomustine was evaluated in 38 cats with confirmed mast cell tumors. Lomustine was administered at a dose at or equal to 50 mg/m(2). Of the 38 cats, most (68%) had cutaneous MCTs but tumors were also diagnosed in other locations, such as mesenteric lymph nodes. The overall response rate was 50%, with 7 cats having a complete response. The median duration of response was 168 days. The most commonly noted toxicoses were neutropenia and thrombocytopenia. The researchers conclude that lomustine should be considered for cats with MCTs where local treatment is not an option.
>> PubMed abstract


Related articles:
Turrel, J., J. Farrelly, et al. (2006). "Evaluation of strontium 90 irradiation in treatment of cutaneous mast cell tumors in cats: 35 cases (1992-2002)." J Amer Vet Med Assoc 228(6): 898-901.
>> PubMed abstract


More on cat health: Winn Feline Foundation Library

Retroviruses and Cat Bite Wounds

Goldkamp, C. E., J. K. Levy, et al. (2008). "Seroprevalences of feline leukemia virus and feline immunodeficiency virus in cats with abscesses or bite wounds and rate of veterinarian compliance with current guidelines for retrovirus testing." J Am Vet Med Assoc 232(8): 1152-8.

In this prospective study, data was collected on 967 cats being treated for bite wounds and abscesses from 134 veterinary practices in 30 states. Cats were tested for feline leukemia virus (FeLV) and feline immunodeficiency virus (FIV) at the time of presentation. Veterinarians were asked to retest cats 60 days later to determine if seronegative cats became positive after the high-risk event. The FeLV-FIV status of 96 cats was known prior to the bite wound event. At the time of treatment, 19.3% of cats were seropositive for FeLV and/or FIV. Risk factors associated with seropositive status included age (adult), gender (male), history of wounds, and outdoor access. Retesting of seronegative cats was recommended to owners of 478 cats at 54.5% of the practices. However, only 13.4% of cats were restested. Of these cats, 5.2% that were initially seronegative for FIV seroconverted. This study determined that a high proportion of cats with abscesses or bite wounds were seropositive for retrovirus infection. Unfortunately, compliance with recommendations to test cats at the time of the event or after treatment was low. Clearly, the FeLV-FIV status of cats with fight wounds should be determined at the time of treatment, and seronegative cats should be retested in 60 days.
>> PubMed abstract

Related articles:
Levy, J. K., H. M. Scott, et al. (2006). "Seroprevalence of feline leukemia virus and feline immunodeficiency virus infection among cats in North America and risk factors for seropositivity." J Am Vet Med Assoc 228(3): 371-6.
>> PubMed abstract

More on cat health: Winn Feline Foundation Library

Cat Scratch Disease: A Review

Breitschwerdt, E. B. (2008). "Feline bartonellosis and cat scratch disease." Vet Immunol Immunopathol 123(1-2): 167-71.

Cat scratch disease (bartonellosis) is caused by various species of Bartonella, intracellular bacteria that favour red blood cells. Cats can be infected with five Bartonella species, including B. henselae and B. clarridgeae. Humans and many domestic animals, such as cattle and dogs, can also serve as chronically infected reservoir hosts for Bartonella. Many arthropod vectors, such as biting flies, fleas and ticks have been implicated in transmission of Bartonella to animals and humans. Bartonella infection can cause various problems in humans, including endocarditis, granulomatous inflammation of lymph nodes, and central nervous system dysfunction. Bartonellosis can be diagnosed in cats with serology, PCR, and culture. However, the issue is clouded by the high rate of sub-clinical infections in cats, making it very difficult to confirm bartonellosis as the cause of illness in cats. Fleas are involved in transmission from cat to cat, so the use of flea control products is critically important to decrease the risk of transmission of Bartonella among cats and to humans.
>> PubMed abstract

Related articles:
Chomel, B. B., H. J. Boulouis, et al. (2006). "Bartonella spp. in pets and effect on human health." Emerg Infect Dis 12(3): 389-94.
>> Free full text article

More on cat health: Winn Feline Foundation Library

Treatment of Ringworm in Shelter Cats

Newbury, S., K. Moriello, et al. (2007). "Use of lime sulphur and itraconazole to treat shelter cats naturally infected with Microsporum canis in an annex facility: an open field trial." Vet Dermatol 18(5): 324-31.

Dermatophytosis is the most common contagious skin disease of cats. It is often a concern in shelter situations since it is zoonotic and highly contagious. It is important to find an effective and rapid treatment protocol for cats with ringworm in shelters to expedite cure and adoption. This open clinical trial in a shelter enrolled 58 cats with confirmed Microsporum canis infection and 32 uninfected bonded pairs. The cats were treated with 21 days of oral itraconazole at 10 mg/kg and twice weekly lime sulphur rinses until cured. No hair coat clipping was performed. Fungal cultures were performed once weekly on all cats. Cats were considered cured with two consecutive negative cultures. No cats developed oral ulcerations as a result of grooming after lime sulphur treatment. No uninfected cats living in contact with infected cats developed dermatophytosis. The mean number of days of treatment required for cure was 18.4 (range 10-49 days). In this shelter, a combination of oral itraconazole and topical lime sulphur treatment was effective and safe.
>> PubMed abstract

Related articles:
Moriello, K. A. and M. Verbrugge (2007). "Use of isolated infected spores to determine the sporocidal efficacy of two commercial antifungal rinses against Microsporum canis." Vet Dermatol 18(1): 55-8.
>> PubMed abstract

More on cat health: Winn Feline Foundation Library

Heartworm in Cats

Litster, A. L. and R. B. Atwell (2008). "Feline heartworm disease: a clinical review." J Feline Med Surg 10(2): 137-44.

Heartworm disease is caused by Dirofilaria immitis and is transmitted by mosquitoes in heartworm-endemic areas around the world. Dogs and other canids are the definitive hosts, but cats can also be infected. In endemic areas, it is estimated that the feline infection rate is about 5-10% of the canine infection rate. While many cats infected with heartworm have no signs of disease, others may have chronic respiratory signs similar to asthma, or chronic vomiting, or acute death. Diagnosis of feline heartworm is challenging, as there is no single perfect test methodology. Treatment is also problematic as there are no adulticides judged to be safe and effective in cats. Most infected cats are managed with supportive care. A number of safe and effective drugs are available for prevention of heartworm infection in cats, in both oral and topical formulations.
>> PubMed abstract

Related articles:
Hoch, H. and K. Strickland (2008). "Canine and feline dirofilariasis: life cycle, pathophysiology, and diagnosis." Comp Contin Edu Vet 30(3): 133-141.
>> PubMed abstract

Hoch, H. and K. Strickland (2008). "Canine and feline dirofilariasis: prophylaxis, treatment, and complications of treatment." Comp Contin Edu Vet 30(3): 146-151.
>> PubMed abstract

KNOW Heartworms

More on cat health: Winn Feline Foundation

Continuous Glucose Monitoring for Diabetic Cats

Wiedmeyer, C. E. and A. E. Declue (2008). "Continuous glucose monitoring in dogs and cats." J Vet Intern Med 22(1): 2-8.


Continuous glucose monitoring systems originally designed for human diabetic patients have been adapted for use in dogs and cats. Sensors continually measure glucose in subcutaneous interstitial fluid (ISF), rather than in blood. A small, flexible sensor is inserted through the skin into the subcutaneous space, secured to the skin, and attached to a recording device. The ISF glucose is recorded and stored every 5 minutes (288 readings per 24 hours). After the device is removed, the data are downloaded to a computer for analysis. The instrument can remain in place for several days, hospitalization of the patient is not necessary, and the normal daily routine of the animal can be maintained. This review from the University of Missouri-Columbia is designed to describe the technology behind the continuous glucose monitoring system, describe the clinical use of the instrument, provide clinical examples in which it may be useful, and discuss future directions for continuous glucose monitoring in dogs and cats.
>> PubMed abstract


Related articles:
Ristic, J. M., M. E. Herrtage, et al. (2005). "Evaluation of a continuous glucose monitoring system in cats with diabetes mellitus." J Feline Med Surg 7(3): 153-62.
>> PubMed abstract


More on cat health: Winn Feline Foundation Library

Pyruvate Kinase Deficiency in Abyssinian & Somali Cats

Kohn, B. and C. Fumi (2008). "Clinical course of pyruvate kinase deficiency in Abyssinian and Somali cats." J Feline Med Surg 10(2): 145-53.

Pyruvate kinase (PK) is one of the key regulatory enzymes for energy generation in red blood cells (RBCs). A deficiency in one PK isoenzyme leads to energy deprivation within the RBCs, resulting in a shortened survival time and hemolysis. PK deficiency has been described in several species, including humans and dogs. The first case of feline PK deficiency was identified in 1992 in an Abyssinian cat. The disease has since been identified in the related Somali breed, as well as in a few domestic shorthair cats. PK deficiency is transmitted as an autosomal recessive trait. The molecular defect has been identified and a genetic screening test has been developed. The objective of this study performed in Berlin, Germany was to examine the clinical signs, laboratory parameters, and course of disease in Abyssinian and Somali cats with PK deficiency. Over a period ranging from under 1 year to over 11 years (median 4.3), the disease was monitored in 25 PK-deficient cats. According to the owners, 11 cats did not show signs of disease. In the other 14 cats, clinical signs included lethargy, diarrhea, pale mucous membranes, anorexia, weight loss, among others. Laboratory abnormalities included anemia, increased aggregated reticulocyte counts, hyperglobulinemia, hyperbilirubinemia, and increased liver enzymes. PK deficiency shows variation in age of onset and severity of signs. Abyssinian and Somali cats destined for breeding should be tested as PK-deficient cats can be asymptomatic.
>> PubMed abstract


Josephine Deubler Genetic Disease Testing Laboratory, University of Pennsylvania


More on cat health: Winn Feline Foundation Library

Feline Dysautonomia in the United States

Kidder, A. C., C. Johannes, et al. (2008). "Feline dysautonomia in the Midwestern United States: a retrospective study of nine cases." J Feline Med Surg 10(2): 130-6.


Dysautonomia in domestic animals results in clinical signs related to dysfunction or failure of the sympathetic and parasympathetic nervous systems. The disease was first reported in cats in 1982 in the United Kingdom, where it is often called Key-Gaskell syndrome. The disease remains uncommon in the United States. Common clinical findings include depression, anorexia, dysphagia, regurgitation or vomiting, constipation, dilated unresponsive pupils, prolapsed nictitating membranes, dry nose and mouth, reduced tear production, bradycardia, and megaesophagus. No etiology is known for this disease in any species although a neurotoxin or an infectious agent has been suggested. This study reports on 9 cases of feline dysautonomia in eastern Kansas and western Missouri. Interestingly, most cases of canine dysautonomia have occurred in eastern Kansas and western and southern Missouri. Unfortunately, feline dysautonomia is associated with a poor prognosis. Only 1 cat in this study could be classified as making a recovery.
>> PubMed abstract


Related articles:
Nunn, F., T. Cave, et al. (2004). "Association between Key-Gaskell syndrome and infection by Clostridium botulinim type C/D." Vet Rec 155(4): 111-115.
>> PubMed abstract


Cave, T., C. Knottenbelt, et al. (2003). "Outbreak of feline dysautonomia (Key-Gaskell syndrome) in a closed colony of pet cats." Vet Rec 153(13): 387-392.
>> PubMed abstract


More on cat health: Winn Feline Foundation Library

Renal Failure Associated with Tainted Pet Food

Brown, C. A., K. S. Jeong, et al. (2007). "Outbreaks of renal failure associated with melamine and cyanuric acid in dogs and cats in 2004 and 2007." J Vet Diagn Invest 19(5): 525-31.

Contaminated pet food caused the death or illness of an unknown number of cats and dogs, most recently in 2007. Initial reports of the cause were confusing and contradictory, but over time, the toxicity was traced to food adulterated with melamine and cyanuric acid. This study from the University of Georgia evaluated histopathologic, toxicologic, and clinicopathologic changes in 16 animals (6 dogs and 10 cats) affected in outbreaks of pet food-associated renal failure in 2004 and 2007. All affected animals had evidence of uremia with anorexia, vomiting, lethargy, polyuria, azotemia and hyperphosphatemia. All animals either died or were euthanized due to severe renal failure. Lesions were found in the distal tubules of the kidneys of all animals at necropsy. Unique crystals were found in the distal tubules or collecting ducts of the kidneys in all animals. Renal tissue from all animals contained melamine and cyanuric acid. This study provides further evidence that melamine and cyanuric acid causes renal failure in cats and dogs.
>> PubMed abstract

Related articles:
Puschner, B., R. H. Poppenga, et al. (2007). "Assessment of melamine and cyanuric acid toxicity in cats." J Vet Diagn Invest 19(6): 616-24.
>> PubMed abstract

More on cat health: Winn Feline Foundation Library

Tritrichomonas Infection in the Uterus of a Cat

Dahlgren, S. S., B. Gjerde, et al. (2007). "First record of natural Tritrichomonas foetus infection of the feline uterus." J Small Anim Pract 48(11): 654-7.

Tritrichomonas foetus is an emerging intestinal parasite of cats, causing chronic large bowel diarrhea. In cattle, this protozoan parasite is a sexually transmitted pathogen, infecting the uterus of cows and the preputial cavity and urethral orifice of bulls. In this case report, the first feline record of T. foetus infection of the uterus is described in a 17-month old Exotic Shorthair queen in Norway with pyometra. This queen had no history of diarrhea. Three other cats in the cattery were diagnosed with T. foetus infection using PCR on fecal samples: a 4.5-year old Persian male with intermittent diarrhea, a 22-month old male Exotic Shorthair with normal feces, and a 2.5-year old female Persian with normal feces. Interestingly, T. foetus has never been identified in cattle in Norway, although it is a reportable disease.
>> PubMed abstract


Related articles:
Winn funded research
Kather, E. J., S. L. Marks, et al. (2007). "Determination of the in vitro susceptibility of feline Tritrichomonas foetus to 5 antimicrobial agents." J Vet Intern Med 21(5): 966-70.
>> PubMed abstract


More on cat health: Winn Feline Foundation Library

Quality of Life for Cats Receiving Chemotherapy

Tzannes, S., M. F. Hammond, et al. (2008). "Owners 'perception of their cats' quality of life during COP chemotherapy for lymphoma." J Feline Med Surg 10(1): 73-81.


Lymphoma is one of the most common feline cancers and many owners opt for chemotherapy as a treatment option. Most owners are concerned about quality of life for feline cancer patients, both with and without chemotherapy. Questionnaires on quality of life (QOL) were completed by the owners of 31 cats undergoing treatment for lymphoma between 2002 and 2006. All cats were treated with cyclophosphamide, vincristine, and prednisolone (COP). QOL scores were significantly higher in cats before the onset of cancer than after, but before the start of chemotherapy. During chemotherapy, QOL scores were also lower than before the onset of cancer, but were significantly higher than prior to starting treatment. The majority of cats (87%) experienced adverse effects during treatment. Most pet owners (83%) were happy they treated their cats and most (87%) would treat another cat. The results of this questionnaire survey indicate that COP chemotherapy is well tolerated by cats according to owner perceptions of QOL.
>> PubMed abstract


Related articles:
Teske, E., G. van Straten, et al. (2002). "Chemotherapy with cyclophosphamide, vincristine, and prednisone (COP) in cats with malignant lymphoma: new results with an old protocol." J Vet Intern Med 16(2): 179-186.
>> PubMed abstract


More on cat health: Winn Feline Foundation

Spironolactone in Cats With Heart Disease

Macdonald, K. A., M. D. Kittleson, et al. (2008). "Effect of spironolactone on diastolic function and left ventricular mass in Maine Coon cats with familial hypertrophic cardiomyopathy." J Vet Intern Med 22(2): 335-41.

Hypertrophic cardiomyopathy (HCM) is a primary myocardial disease affecting the left ventricle. Some of the pathologic abnormalities found in HCM are myocardial fibrosis and concentric hypertrophy. Treatments that would reverse these pathologic changes would be beneficial. In a rat model of HCM, spironolactone reversed interstitial fibrosis, decreased myocyte disarray by 50%, and improved diastolic function within 10 weeks of treatment. The goal of this study was to evaluate spironolactone treatment of Maine Coon cats with HCM for its ability to improve diastolic function and reduce left ventricular mass. The study enrolled 26 Maine Coon cats with familial HCM and randomized them into two groups. One group received spironolactone (2 mg/kg, PO, BID) and the other group received placebo for 4 months. No significant treatment effect on cardiac function or left ventricular mass was identified. Severe facial dermatitis developed in 4 of the 13 cats receiving spironolactone, requiring discontinuation of therapy.

>> PubMed abstract

Related articles:

Winn funded research

Meurs, K., X. Sanchez, et al. (2005). "A cardiac myosin binding protein C mutation in the Maine Coon cat with familial hypertrophic cardiomyopathy." Hum Mol Genet 14(23): 3587-3593.

>> PubMed abstract

More on cat health: Winn Feline Foundation Library

Cytauxzoonosis in Domestic Cats

Reichard, M. V., K. A. Baum, et al. (2008). "Temporal occurrence and environmental risk factors associated with cytauxzoonosis in domestic cats." Vet Parasitol 152(3-4): 314-20.

Cytauxzoonosis is caused by Cytauxzoon felis, a protozoan parasite of domestic and wild cats that is transmitted by ticks. The disease is seen in the south-central and southeastern U.S. Cytauxzoonosis is typically a severe disease in domestic cats, with fever , anorexia, anemia, and icterus. Most affected cats die within 3 weeks. This study determined the temporal occurrence and risk factors associated with C. felis infection in domestic cats in Oklahoma with a retrospective search of electronic medical records from the Oklahoma Animal Disease Diagnostic Laboratory and the Boren Veterinary Medical Teaching Hospital. From 1995 to 2006, a total of 232 cytauxzoonosis cases were identified and analyzed. The number of cases remained constant from year to year. Diagnosis of the disease followed a bimodal pattern, with most cases diagnosed in April-June and a smaller number in August-September. In cases where a client address was known, the majority occurred in low density residential areas. Cytauxzoonosis cases were significantly associated with more wooded cover and closer proximity to natural or unmanaged areas than control sites. More cases can be expected in domestic cats living in close proximity to environments that support both ticks and bobcats.
>> PubMed abstract

Related articles:
Haber, M. D., M. D. Tucker, et al. (2007). "The detection of Cytauxzoon felis in apparently healthy free-roaming cats in the USA." Vet Parasitol 146(3-4): 316-20.
>> PubMed abstract

Birkenheuer, A., J. Le, et al. (2006). "Cytauxzoon felis infection in cats in the mid-Atlantic states: 34 cases (1998-2004)." J Amer Vet Med Assoc 228(4): 568-571.
>> PubMed abstract

More on cat health: Winn Feline Foundation Library

Carboplatin For Treatment Of Cancer in Cats

Kisseberth, W. C., D. M. Vail, et al. (2008). "Phase I clinical evaluation of carboplatin in tumor-bearing cats: a veterinary cooperative oncology group study." J Vet Intern Med 22(1): 83-8.


Carboplatin (Paraplatin, Bristol-Myers Squibb) is an alkylating agent widely used as chemotherapy for certain tumors in humans and dogs. In cats, only isolated case reports exist. Little investigation has been done to investigate the optimal dose and efficacy of this drug in cats with tumors. In this study, 59 cats with naturally occurring solid tumors were treated with carboplatin. Cats were enrolled in the study from several different institutions and had various tumor types, such as injection-site sarcomas and oral squamous cell sarcomas. The starting dose was 160 mg/m(2) of body surface area and the dose was increased in cohorts of cats until the maximally tolerated dose was determined. The maximally tolerated dose was 240 mg/m(2) and the dose limiting toxicity was neutropenia. The lowest neutrophil and platelet counts occurred 2 to 3 weeks after drug administration. There was no evidence of drug-induced kidney toxicity or pulmonary edema. There was one cat with complete response to treatment, and six cats with partial responses. The dose of carboplatin recommended by the researchers is 240 mg/m(2) IV every 3 to 4 weeks. Carboplatin appears to be safe and well tolerated in cats.
>> PubMed abstract


Veterinary Cancer Society


More on cat health: Winn Feline Foundation Library

Seizures in Cats with FIP

Timmann, D., S. Cizinauskas, et al. (2008). "Retrospective analysis of seizures associated with feline infectious peritonitis in cats." J Feline Med Surg 10(1): 9-15.

Seizures have been reported frequently in feline infectious peritonitis (FIP) but have not been studied in detail in association with this disease. The purpose of this study was to perform a retrospective analysis of neurological signs in a population of 55 cats with a histopathologically confirmed neurological form of FIP. Seizure patterns were determined and it was attempted to relate occurrence of seizures with age, breed, sex and neuropathological features. Fourteen cats had seizure(s), while 41 cats had no history of seizure(s). Generalised tonic-clonic seizures were seen in nine cats; and complex focal seizures were observed in four patients. The exact type of seizure could not be determined in one cat. Status epilepticus was observed in one patient but seizure clusters were not encountered. Occurrence of seizures was not related to age, sex, breed or intensity of the inflammation in the central nervous system. However, seizures were significantly more frequent in animals with marked extension of the inflammatory lesions to the forebrain (P=0.038). Thus, the occurrence of seizures in FIP indicates extensive brain damage and can, therefore, be considered to be an unfavourable prognostic sign.
>>PubMed abstract

Related articles:
Winn funded research
Foley, J., C. Rand, et al. (2003). "Inflammation and changes in cytokine levels in neurological feline infectious peritonitis." J Fel Med Surg 5(6): 313-322.
>>PubMed abstract

More on cat health: Winn Feline Foundation Library

Safety of IV Famotidine in Cats

de Brito Galvao, J. F. and L. A. Trepanier (2008). "Risk of hemolytic anemia with intravenous administration of famotidine to hospitalized cats." J Vet Intern Med 22(2): 325-9.

Famotidine is a histamine type 2 blocker, used to treat esophagitis, nausea and vomiting in cats. Anecdotally, famotidine has been associated with hemolytic anemia when given intravenously to cats, leading some clinicians to avoid this route of administration. The actual risk has not been fully evaluated, and many clinicians have never experienced adverse effects from IV use of famotidine in cats. The objective of this study was to determine if a significant drop in packed cell volume (PCV) was observed in hospitalized cats given famotidine IV compared to cats given the drug by the subcutaneous route (SC), or not at all. It was also hypothesized that when famotidine is given slowly IV, no signficant decrease in PCV would occur. A retrospective medical record review was performed involving 56 cats prescribed famotidine IV, 48 cats given famotidine SC, and 38 cats that were not prescribed the drug at all (control group). The IV famotidine was given by a standardized protocol in this study, with administration over a period of 5 minutes. No cats were given famotidine by rapid IV bolus. The median decrease in PCV was no different in cats that received famotidine by either route compared with the control group. No cats in the famotidine groups had any signs of hemolysis. In this retrospective study, famotidine was given IV to 56 hospitalized cats without evidence of hemolysis, and the IV route appeared safe when the drug was administered over 5 minutes. There did not appear to be a safety advantage of SC versus IV administration in this group of cats.
>> PubMed abstract

More on cat health: Winn Feline Foundation Library

Measurement of Heart Size in Cats

Ghadiri, A., R. Avizeh, et al. (2008). "Radiographic measurement of vertebral heart size in healthy stray cats." J Feline Med Surg 10(1): 61-5.

Determination of heart size on chest radiographs is important when evaluating cats for cardiac disease. An enlarged cardiac silhouette is an indicator of cardiac disease. However, determination of cardiac size is usually subjective. In recent years, a cardiac measurement technique called the vertebral heart size or score (VHS) has been investigated as a less biased assessment of cardiac size. VHS compares cardiac dimensions with the length of mid-thoracic vertebrae. It has previously been evaluated in mixed groups of obese and non-obese cats of various ages, breeds, and sizes. Different breeds of dogs may have different normal reference values for VHS but it is not known if there is variability in normal reference values for different populations of cats. The objective of this study was to determine VHS in clinically normal, domestic shorthair, non-obese stray cats. The study was performed in Ahvaz, Iran. Left and right lateral, dorsoventral and ventrodorsal radiographs were taken and evaluated. Absolute measurements and vertebral heart scale values were slightly smaller than those previously reported in the literature, indicating that normal reference values may vary by breed or population in cats.
>> PubMed abstract

Related articles:
Litster, A. and J. Buchanan (2000). "Vertebral scale system to measure heart size in radiographs of cats." J Amer Vet Med Assoc 216(2): 210-214.
>> PubMed abstract

More on cat health: Winn Feline Foundation Library

Blood Pressure and Survival in Sick Cats

Silverstein, D. C., F. A. Wininger, et al. (2008). "Relationship between Doppler blood pressure and survival or response to treatment in critically ill cats: 83 cases (2003-2004)." J Am Vet Med Assoc 232(6): 893-7.

Critically ill cats pose special challenges in veterinary medicine. Standard means of monitoring cardiovascular status include temperature, respiratory rate, pulse rate (TPR) and blood pressure (BP). Both Doppler and oscillometric methods are routinely used to monitor BP in cats. Hypotension in cats is defined as a BP of under 80-90 mm Hg. Intermittent or prolonged hypotension can lead to serious consequences, such as impaired perfusion and decreased oxygen delivery, causing organ damage or failure. The purpose of this study was to evaluate the relationship between Doppler BP and survival or response to treatment in critically ill cats. The study is a retrospective case series involving the records of 83 cats. In addition to BP, other factors evaluated included survival to discharge, heart rate, rectal temperature, packed cell volume (PCV), plasma pH, serum ionized calcium, disease process, body weight, age, duration of hospitalization, and catecholamine treatment. Of the 83 cats, 39 were considered hypotensive and 44 were normotensive. Overall survival rate was 53%, with a significantly higher mortality rate amongst hypotensive patients. Of the other variables, only low rectal temperature and low PCV were significantly associated with hypotension. Monitoring for and correcting hypotension should be addressed in hospitalized, critically ill cats.
>> PubMed abstract

Related articles:
Lin, C. H., C. J. Yan, et al. (2006). "Systolic blood pressure of clinically normal and conscious cats determined by an indirect Doppler method in a clinical setting." J Vet Med Sci 68(8): 827-32.
>> Free, full text article

More on cat health: Winn Feline Foundation Library

Levetiracetam for Epilepsy in Cats

Bailey, K. S., C. W. Dewey, et al. (2008). "Levetiracetam as an adjunct to phenobarbital treatment in cats with suspected idiopathic epilepsy." J Am Vet Med Assoc 232(6): 867-72.

Levetiracetam (Keppra, UCB Pharma) is an anticonvulsant medication licensed for the treatment of epilepsy in humans. Anecdotally, it has been used as adjunctive therapy for epilepsy in dogs and cats. The goal of this study was to assess the pharmacokinetics, efficacy and adverse effects of oral levetiracetam administered in conjunction with phenobarbital in cats with poorly controlled epilepsy. The study was designed as an open-label, noncomparative clinical trial. Twelve cats with epilepsy poorly controlled by phenobarbital or that had unacceptable adverse effects from phenobarbital were enrolled in the study. The cats were treated with levetiracetam at 20 mg/kg every 8 hours. Serum drug levels were measured after at least 1 week of treatment. Seizure frequency before and after initiation of therapy were compared, and any adverse effects were recorded. The median serum half-life for levetiracetam was 2.9 hours. Seizure frequency was significantly higher prior to treatment with levetiracetam (2.1 seizures/month versus 0.42 seizures/month). Seven of 10 cats had reduction in seizure frequency of equal to or greater than 50%. Two cats had transient lethargy and anorexia. The researchers conclude that levetiracetam is well tolerated in cats, and may be a useful adjunct therapy to phenobarbital for cats with idiopathic epilepsy.
>> PubMed abstract

Related articles:
Dewey, C. W. (2006). "Anticonvulsant therapy in dogs and cats." Vet Clin North Am Small Anim Pract 36(5): 1107-27, vii.
>> PubMed abstract

More on cat health: Winn Feline Foundation Library

New Antiviral Treatment for Feline Calicivirus

Smith, A. W., P. L. Iversen, et al. (2008). "Virus-specific antiviral treatment for controlling severe and fatal outbreaks of feline calicivirus infection." Am J Vet Res 69(1): 23-32.

During the past decade, several outbreaks of severe systemic disease associated with feline calicivirus (FCV) have occurred with high mortality in the affected animals. This study details evaluation of a virus-specific antiviral phosphorodiamidate morpholino oligomer (PMO) for treating 112 kittens involved in 3 natural outbreaks of disease in the United States. PMOs are molecules used to modify gene expression. This novel treatment modality has not previously been tested in cats. A calicivirus strain was isolated from a cat that died of natural hemorrhagic calicivirus disease and a PMO was synthesized. The PMO was administered on day 1 of clinical signs and continued for up to 7 days. Various antiviral doses were evaluated by comparing survival times, clinical recovery, and virus shedding. In the natural outbreaks, 47 of 59 treated cats survived, but only 3 of 31 untreated cats survived. PMO treatment reduced calicivirus shedding and improved clinical recovery. Virus-specific PMOs may be an effective modality for treatment of severe disease associated with feline calicivirus.
>> PubMed abstract

Related blog posts:
Virulent systemic calicivirus
Feline caliciviruses causing virulent systemic disease are genetically distinct


More on PMOs


More on cat health: Winn Feline Foundation Library